Core Viewpoint - The withdrawal of ORMD-0801 by Tianhui Biotech highlights the long-term uncertainty surrounding the oral insulin market, which is considered a high-difficulty area in the pharmaceutical industry [6][12]. Group 1: Product Development and Market Potential - ORMD-0801 aims to address a long-standing challenge in medicine by enabling oral administration of insulin, which offers advantages in patient compliance and long-term treatment experience compared to injectable forms [7]. - The global diabetes patient population is large, making the insulin market attractive, especially for type 2 diabetes patients who often rely on exogenous insulin due to the depletion of their own pancreatic beta-cell function [7][8]. Group 2: Technological and Strategic Background - ORMD-0801 is not a homegrown product but was introduced to Tianhui Biotech from the Israeli company Oramed in 2015, which specializes in oral delivery technology for proteins [9]. - Oramed's POD™ technology aims to protect insulin from gastric acid and facilitate its absorption in the intestines, a challenge that many pharmaceutical companies have faced [9]. Group 3: Clinical Trials and Regulatory Challenges - ORMD-0801 completed its Phase III clinical trial in China in 2022 and was submitted for approval in April 2023, but faced controversy due to the failure of a similar trial in the U.S. [10]. - Despite the U.S. trial's failure, Tianhui Biotech maintained that the differences in clinical trial designs would not affect expectations in China, although this raised regulatory scrutiny [10]. Group 4: Financial and Operational Issues - In August 2023, Oramed and Tianhui Biotech announced plans to establish a joint venture, OraTech, to focus on global registration of the oral insulin pipeline, with both parties investing significant amounts [11]. - However, the joint venture was terminated in October 2025 due to Tianhui Biotech's failure to meet financial conditions, limiting its ability to participate in global expansion [11]. Group 5: Industry Trends and Future Outlook - Tianhui Biotech faces operational challenges, including tax issues and contract disputes, raising concerns about its stability [12]. - The approval of long-acting insulin products by competitors, such as Novo Nordisk, is reducing the urgency for oral insulin solutions, indicating a shift in the market landscape [12]. - The withdrawal of ORMD-0801 does not signify the end of oral insulin development but underscores the high investment and failure rates in this challenging field [13].